Navigation Links
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Date:9/25/2011

00 mg once-daily, which was increased to 400 mg once-daily after two weeks if well tolerated. The dose could be reduced to 200 mg once-daily if treatment was not well tolerated(1).

QTI571 is currently not approved to treat PAH and is planned to be submitted for regulatory approval later this year for the treatment of this disease. Imatinib, the active ingredient in QTI571, is currently available under the trade names Glivec® and Gleevec® for use in certain oncology indications.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "potential," "can," "estimated," "committed," "planned," or similar expressions, or by express or implied discussions regarding potential marketing approvals for QTI571 or regarding potential future revenues from QTI571. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with QTI571 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that QTI571 will be approved for sale in any market. Nor can there be any guarantee that QTI571 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding QTI571 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values att
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
(Date:9/22/2014)... YORK , September 22, 2014 ... Market Report on "Global Market Study on Ophthalmic Devices: ... by 2020," the global ophthalmic devices market was valued at USD ... at a CAGR of 6.5% from 2014 to 2020, ... in 2020. Browse the full Global Market Study ...
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2
... MARY, Fla., Jan. 26, 2012   In a pediatric ... caring environment, Middleton Pediatrics is one of the first ... to assess their young patients vision.  This revolutionary vision ... important vision data in one second or less.  ...
... 26, 2012  Aria Diagnostics, a molecular diagnostics company, ... study that examines the accuracy of its non-invasive ... (associated with Down syndrome) and Trisomy 18 (associated ... test, coupled with a proprietary algorithm to assess ...
Cached Medicine Technology:Middleton Pediatrics Now Using Spot to Screen Patients 2Middleton Pediatrics Now Using Spot to Screen Patients 3Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology 2
(Date:9/22/2014)... RI (PRWEB) September 22, 2014 Severe weather can ... of time. That’s why, as part of National Preparedness Month, ... and your family prepare for the unexpected:, , ... well as nonperishable food and one gallon of water per person ... Create an evacuation plan that includes pets so your family ...
(Date:9/22/2014)... / Westchester County, NY (PRWEB) September 22, 2014 ... (NYGPS) has joined the Department of Surgery at the ... named Mount Sinai Doctors New York Group for Plastic ... lower Hudson Valley access to a team of world-renowned ... techniques. Additionally, C. Andrew Salzberg, MD, who led ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... The report segments the global physiotherapy equipment ... The equipment segment accounted for a lion’s share ... However, the accessories segment is expected to grow ... owing to the rising demand of physiotherapy services ... are the fastest-growing segments in the physiotherapy equipment ...
(Date:9/22/2014)... critical information systems, such as medical records in ... new approach to computer security that authenticates users ... automatically logs them out when they leave or ... terminal. , Dartmouth,s Trustworthy Health and Wellness ... at the IEEE Symposium on Security & ...
Breaking Medicine News(10 mins):Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3
... Patient Satisfaction Scores Through Implementing the RROHC Bundle of ... Feb. 27 -- Hansten Healthcare PLLC , a ... and skill development and improving patient satisfaction scores, today ... company as faculty and RROHC Master Coach. , ...
... LAS VEGAS, Feb. 27 Orthopaedic surgeon David ... Specialty Societies (BOS), of the American Academy of Orthopaedic ... Meeting. Dr. Polly will also sit on the Academy,s ... in the Department of Orthopaedic Surgery at the University ...
... United States have used yeast and mammalian cells to ... Parkinson,s disease. , Yeasts are single cell organisms, ... that of cells found in animals and humans. Yeasts ... and offer the ability to screen or test thousands ...
... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... procedure pursuant to Law 223/1991 concerning its Bresso, Italy, ... total of 62 employees. Within 75 days of ... Trade Unions, will review solutions that may reduce the ...
... shares poetry author,s two-year period of severe depressionBROOKLYN, N.Y., ... Arthur F. Temple kept a journal, in which the ... had become intolerable, and the result is this fascinating ... ).In nearly 100 poems, Temple shares his heartfelt feelings ...
... Driven by Demand for Branded Products- Adjusted Diluted EPS ... 2009 Adjusted EPS Guidance Range of $2.59 - $2.67CHADDS ... ENDP ) today reported double-digit percentage growth in ... the fourth quarter and full year ended December 31, ...
Cached Medicine News:Health News:Relationship and Results Oriented Healthcare Announces New Faculty With Impressive Patient Satisfaction Scores 2Health News:David W. Polly Jr., MD, Elected Secretary of Academy Board of Specialty Societies 2Health News:How yeast is helping us to understand Parkinson's Disease 2Health News:How yeast is helping us to understand Parkinson's Disease 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 2Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 3Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 4Health News:CTI Focuses on Late-Stage Drug Approvals and Commercialization and Cuts Operating Costs: to Close Bresso Research Center 5Health News:Journey into the Dark Recesses of the Subconscious Mind 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 4Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 5Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 6Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 7Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 8Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 9Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 10Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 11Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 12Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 13Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 14
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
... on patented microplate agglutination technology. Its is ... donor ABO/Rh testing. PK7200 also handles weak ... antibody detection. The Automated Microplate System delivers ... proven reliability that for the past generation ...
... Tecan Haemotyper is an automated ... The Tecan Haemotyper combines a ... platform with the DiaMed agglutination ... process DiaMed-ID cards and microplates ...
... Since the early 1990s, the "Reversed" ... shoulder surgeons with great success. More recently, ... United States have begun to champion this ... go with it. This reversed technology is ...
Medicine Products: